[Consensus document for the treatment of bacteremia and endocarditis caused by methicillin-resistent Staphylococcus aureus. Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica].
Bacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus (MRSA) are prevalent and clinically important. The rise in MRSA bacteremia and endocarditis is related with the increasing use of venous catheters and other vascular procedures. Glycopeptides have been the reference drugs for treating these infections. Unfortunately their activity is not completely satisfactory, particularly against MRSA strains with MICs > 1 microg/mL. The development of new antibiotics, such as linezolid and daptomycin, and the promise of future compounds (dalvabancin, ceftobiprole and telavancin) may change the expectatives in this field.The principal aim of this consensus document was to formulate several recommendations to improve the outcome of MRSA bacteremia and endocarditis, based on the latest reported scientific evidence. This document specifically analyzes the approach for three clinical situations: venous catheter-related bacteremia, persistent bacteremia, and infective endocarditis due to MRSA.
Gudiol
Francisco
F
Servicio de Enfermedades Infecciosas, IDIBELL, Hospital Universitario de Bellvitge, Barcelona, España.
Aguado
José María
JM
Pascual
Alvaro
A
Pujol
Miquel
M
Almirante
Benito
B
Miró
José María
JM
Cercenado
Emilia
E
Domínguez
María de Los Angeles
Mde L
Soriano
Alex
A
Rodríguez-Baño
Jesús
J
Vallés
Jordi
J
Palomar
Mercedes
M
Tornos
Pilar
P
Bouza
Emilio
E
D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D016470:Bacteremia / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology; D002404:Catheterization / Q000009:adverse effects; D002405:Catheterization, Central Venous / Q000009:adverse effects; D002986:Clinical Trials as Topic; D020878:Device Removal; D024901:Drug Resistance, Multiple, Bacterial; D042241:Early Diagnosis; D004697:Endocarditis, Bacterial / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology / Q000601:surgery; D004866:Equipment Contamination; D019317:Evidence-Based Medicine; D006350:Heart Valve Prosthesis / Q000009:adverse effects; D019918:Heart Valve Prosthesis Implantation; D006801:Humans; D016106:Methicillin Resistance; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects / Q000302:isolation & purification*; D008826:Microbial Sensitivity Tests; D015995:Prevalence; D011446:Prospective Studies; D016459:Prosthesis-Related Infections; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology / Q000601:surgery; D014640:Vancomycin / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D014640:Vancomycin